

Express Mail No.: EL197650401US

Docket No.: 21327-701CON2  
F3

**In The United States Patent and Trademark Office**

Applicant: Gill et al.,  
Serial No.: 09/805,761  
Filing Date: March 13, 2001  
Title: Methods and Compositions for Antisense VEGF Oligonucleotides

Examiner: To Be Assigned  
Group Art Unit: 1635

Box Missing Parts  
Commissioner for Patents  
Washington, D.C. 20231

**PETITION TO ACCEPT COLOR PHOTOGRAPHS**  
**(37 C.F.R. §1.84(b)(2))**

Sir:

This petition is for the acceptance of color photographs (37 C.F.R. §1.84(b)(2)).

Attached hereto are three sets of color photographs for Figures 23A-23O of the above referenced application. The reason for the need for color photographs in this application are that color photographs are the practicable media for illustrating fluorescent labeling. Granting of this petition is respectfully requested. An Preliminary Amendment requesting amendment of the specification to refer to the Color Photographs is also filed concurrently herewith.


Please charge Deposit Account No. 50-1189, Docket No.:21327-701CON2, in the amount of \$130.00 to cover the petition fee as set forth in 37 C.F.R. §1.17(h). The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1189, Docket No.:21327-701CON2. *A duplicate of this sheet is enclosed.*

Date: November 16, 2001

11/27/2001 BARBARA M. GRUPPI 50-1189 09805761


02 FD:122 130.00 04

Respectfully submitted,


By:   
Carol M. Gruppi  
Registration No. 37,341

McCutchen, Doyle, Brown & Enersen, LLP  
Three Embarcadero Center, Suite 1800  
San Francisco, California 94111  
Telephone: (650) 849-4902  
Telefax: (650) 849-4800

1 / 29




**FIG.\_1A**



**FIG.\_1B**


2 / 29




**FIG. 2**

3 / 29


	KSY1	HUVE	SKIN	KS lesion	T1	23-1	HUT-78
M	flt KDR	flt KDR	flt KDR	flt KDR	flt KDR	flt KDR	flt KDR



**FIG.\_3A**




**FIG.\_3B**




**FIG.\_4**

4 / 29




**FIG.\_5A**




**FIG.\_5B**

5 / 29




**FIG.\_6A**




**FIG.\_6B**

6 / 29




**FIG.\_6C**




**FIG.\_6D**

7 / 29




**FIG.\_6E**



**FIG.\_6F**

8 / 29

NT	1 $\mu$ M AS-1				5 $\mu$ M AS-1				10 $\mu$ M AS-1						
M	25	29	33	37	41	25	29	33	37	41	25	29	33	37	41




**FIG.\_7A**

NT	1 $\mu$ M AS-3				5 $\mu$ M AS-3				10 $\mu$ M AS-3						
M	25	29	33	37	41	25	29	33	37	41	25	29	33	37	41



**FIG.\_7B**

NT	1 $\mu$ M S				5 $\mu$ M S				10 $\mu$ M S						
M	25	29	33	37	41	25	29	33	37	41	25	29	33	37	41



**FIG.\_7C**


9 / 29

NT	1 $\mu$ MAS1	5 $\mu$ MAS1	10 $\mu$ MAS1
M 18 22 26 30 33	18 22 26 30 33	18 22 26 30 33	18 22 26 30 33




**FIG.\_7D**

NT	1 $\mu$ MAS3	5 $\mu$ MAS3	10 $\mu$ MAS3
M 18 22 26 30 33	18 22 26 30 33	18 22 26 30 33	18 22 26 30 33




**FIG.\_7E**

NT	1 $\mu$ M S	5 $\mu$ M S	10 $\mu$ M S
M 18 22 26 30 33	18 22 26 30 33	18 22 26 30 33	18 22 26 30 33




**FIG.\_7F**


10 / 29



**FIG.\_7G**




**FIG.\_7H**




**FIG.\_7I**


11 / 29



**FIG.\_7J**




**FIG.\_7K**



**FIG.\_8**


12 / 29

Effect of Liposomal VEGF Scrambled ODNs  
on the Cell Growth of KSY-1




**FIG.\_9A**

Effect of Liposomal VEGF AS-3 Antisense ODNs  
on the Growth of KSY-1



**FIG.\_9B**


13 / 29



**FIG.\_ 10A**




**FIG.\_ 10B**




**FIG.\_ 11A**


14 / 29




**FIG.\_ 11B**




**FIG.\_ 11C**



**FIG.\_ 11D**




**FIG.\_ 11E**




**FIG.\_ 11F**

15 / 29



**FIG.\_12**




**FIG.\_13**

\* SEQ ID NO: 9 \_\_\_\_\_ 269-289  
 \* SEQ ID NO: 10 \_\_\_\_\_ 268-288  
 \* SEQ ID NO: 11 \_\_\_\_\_ 267-287  
 \* SEQ ID NO: 12 \_\_\_\_\_ 266-286  
 \*\* SEQ ID NO: 13 \_\_\_\_\_ 265-285  
 \*\* SEQ ID NO: 14 \_\_\_\_\_ 264-284  
 \* SEQ ID NO: 15 \_\_\_\_\_ 263-283  
 \* SEQ ID NO: 16 \_\_\_\_\_ 262-282  
 SEQ ID NO: 30 VEGF-A AGATCGAGTACATCTCAAGGCCATCCTGTGTGCCCCCTG  
 SEQ ID NO: 31 VEGF-C CGACAAACACCTCTTTAACCTCATGTGTTCCGTC  
 SEQ ID NO: 32 VEGF-D GTACCAACACATCTTCAGCCCCCTGTGTGAACGTG  
 \* SEQ ID NO: 29 \_\_\_\_\_ 271-  
 \*\* SEQ ID NO: 2 \_\_\_\_\_ 261-281  
 \* SEQ ID NO: 17 \_\_\_\_\_ 260-280  
 \* SEQ ID NO: 18 \_\_\_\_\_ 259-279  
 \* SEQ ID NO: 20 \_\_\_\_\_ 265-284  
 \* SEQ ID NO: 21 \_\_\_\_\_ 266-284

FIG.-14


*FIG.- 15G*

Control




*FIG.- 15H*

VEGFR-1




*FIG.- 15I*

VEGFR-2




*FIG.- 15J*

Hoc-7  
A375




*FIG.- 15K*

VEGFR-1




*FIG.- 15L*


VEGFR-2




19 / 29



**FIG.\_ 16A**




**FIG.\_ 16B**




**FIG.\_ 16C**

20 / 29

**FIG.\_ 16D**



**FIG.\_ 16E**




**FIG.\_ 16F**



**FIG.\_ 16G**



21 / 29



**FIG.\_ 17A**


VEGFA	ATCGAGTACATCTTCAAGCCA
VEGFB	GTGGCCAAACAGCTGGTGCCC
VEGFC	ACAAACACCTTCTTTAACCT
P1GF	GTGGAGCACATGTTCAAGCCCC
VEGFD	ACCAAACACATTCTTCAAGCCCC

**FIG.\_ 17B**

Human	ATCGAGTACATCTTCAAGCCA
Mouse	ATAGAGTACATCTTCAAGCCG

**FIG.\_ 17C**

22 / 29




**FIG.- 18A**



**FIG.- 18C**




**FIG.- 18E**



**FIG.- 18G**




**FIG.- 18I**




**FIG.- 18B**



**FIG.- 18D**




**FIG.- 18F**




**FIG.- 18H**

23 / 29




**FIG.\_18J**




**FIG.\_18K**


24 / 29



**FIG.\_ 19A**




**FIG.\_ 19C** Concentration of AS-3 (μM)




**FIG.\_ 19D** Concentration of AS-3 (μM)


25 / 29



**FIG.\_20B**




**FIG.\_20C**



**FIG.\_20D**


26 / 29

**FIG.\_21A    FIG.\_21B**



**FIG.\_21C    FIG.\_21D**

**FIG.\_21E    FIG.\_21F    FIG.\_21G**




**FIG.\_21H    FIG.\_21I    FIG.\_21J**

27 / 29


**FIG.\_21K**

VEGF AS-3m




**FIG.\_21L**

VEGF AS-3m



**FIG.\_21M**

VEGF AS-3m




**FIG.\_21N**

VEGF AS-3m


**FIG.\_21O**

VEGF AS-3m


**FIG.\_21P**




**FIG.\_22**




**FIG.\_23A**




**FIG.\_23B**




**FIG.\_23C**




**FIG.\_23D**




**FIG.\_23E**




**FIG.\_23F**




**FIG.\_23G**




**FIG.\_23H**




**FIG.\_23I**






**FIG.\_23J**




**FIG.\_23K**




**FIG.\_23L**







**FIG.\_23A**




**FIG.\_23B**




**FIG.\_23C**



**FIG.\_23D**




**FIG.\_23E**



**FIG.\_23F**




**FIG.\_23G**




**FIG.\_23H**




**FIG.\_23I**




**FIG.\_23J**




**FIG.\_23K**




**FIG.\_23L**




**FIG.\_23M**




**FIG.\_23N**




**FIG.\_23O**




**FIG.\_23A**




**FIG.\_23B**




**FIG.\_23C**




**FIG.\_23D**




**FIG.\_23E**




**FIG.\_23F**




**FIG.\_23G**




**FIG.\_23H**




**FIG.\_23I**




**FIG.\_23J**




**FIG.\_23K**




**FIG.\_23L**




**FIG.\_23M**




**FIG.\_23N**



**FIG.\_23O**



**FIG.\_24A**



**FIG.\_24B**